BACHADON BO‘YNI SARATONI VA SARATONDAN OLDINGI HOLATLARNI ERTA ANIQLASH, OLDINI OLISH VA PROGNOZLASH BO‘YICHA ILG‘OR YUTUQLAR.
##article.subject##:
Bachadon bo'yni kasalliklari, odam papilloma virusinining onkogen shtammlari, minimal invaziv usullar va erta aniqlash##article.abstract##
Bachadon bo'yni saratoni bir qancha onkologik kasalliklar qatoriga kiradi, ular erta aniqlansa, muvaffaqiyatli davolanadi, bu umumiy omon qolish darajasining oshishiga, takrorlanish ehtimolining pasayishiga, bemorlarning hayot sifatini oshirishga va davolanish xarajatlarini kamaytirishga olib keladi. Bachadon bo'yni saratonining asosiy sababi odam papilloma virusining onkogen shtammlari bo'lib, ularni skrining tekshiruvlari orqali oldini olish mumkin.
Библиографические ссылки
Sukhikh GT, Prilepskaya VN, ed. Prevention of cervical cancer: A guide for doctors. 3rd ed. Moscow: MEDpress-inform; 2018. 192p.
Stern P.L., G.S. Kitchener G.S., eds. Vaccine for the prevention of cervical cancer: Per. from English Sukhikh G.T., Prilepskaya V.N., ed.M.: MEDpress-inform; 2019.192c
Rogovskaya S.I. Papillomavirus infection in women and cervix pathology: to help the practitioner. 2nd ed. Moscow: GEOTAR-Media; 2018. 192c
Bleotu C., Botezatu A., Goia C.D., Socolov D., Corniţescu F., Teleman S., et al. P16ink4A-A possible marker in HPV persistence screening. room. Arch. microbiol. Immunol. 2019; 68(3): 183–9.
Davey E., Barratt A., Irwig L., Chan S.F., Macaskill P., Mannes P., Saville A.M. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet. 2016; 376(9505): 122–32.
Franco E.L., Harper D.M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2015; 23(17–18): 2388–94.
Hutchcraft M. L. et al. Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer // Gynecologic oncology. - 2019. - T. 153. - No. 2. – P. 255-258.
Muñoz N., Bosch F.X., Castellsagué X., Díaz M., de Sanjose S., Hammouda D. et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer. 2020; 111(2): 278–85.
Nuovo J., Melnikow J., Howell L.P. New tests for cervical cancer screening. Am. fam. P hysician. 2011; 64:L780–6.
Pierry D., Weiss G., Lack B., Chen V., Fusco J. Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN 2+ in cervical biopsies better than Papanicolaou screening for women regardless of age. Arch. Pathol. Lab. Med. 2012; 136(8): 956–60.
Ramirez P., Frumovitz M., Pareja R. et.al. Phase III randomized trial of laparoscopic or robotic radical hysterectomy vs. abdominal radical hysterectomy in patients with early-stage cervical cancer: LACC Trial. N Engl J Med 2018;379(20):1895–904.
Snijders P., van den Brule A., Meijer C. The clinical relevance of human papillomavirus testing: the relationship between analytical and clinical sensitivity. J. Pathol. 2019; 201(1)
Kurman R.J., Carcangiu M.L., Harrington C.S., et al. (eds.) WHO Classification of Tumors of the Female Reproductive Organs. Geneva, Switzerland: WHO Press, 2018. World Health Organization Classification of Tumors. 4th edition.
Webb J.C., Key C.R., Qualls C.R. et al. Population-based study of microinvasive adenocarcinoma of the uterine cervix. Obstet Gynecol 2018;97(5 Pt 1):701–6.
